Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737484 | 1.00 | RAB9A (0.40) | RAB9ANPC1HPGDSMN1; SMN2POLB | |
| SCHEMBL5737261 | 0.90 | RAB9A (0.41) | RAB9AHPGDSMN1; SMN2MAPTKMT2A | |
| SCHEMBL5737264 | 0.90 | RAB9A (0.41) | RAB9AHPGDSMN1; SMN2MAPTKMT2A | |
| SCHEMBL5738505 | 0.86 | ALDH1A1 (0.47) | RAB9ANPC1HPGDSMN1; SMN2POLB | |
| SCHEMBL5738509 | 0.86 | ALDH1A1 (0.47) | RAB9ANPC1HPGDSMN1; SMN2POLB | |
| SCHEMBL5734287 | 0.86 | ALDH1A1 (0.39) | RAB9AHPGDSMN1; SMN2POLBMAPT | |
| SCHEMBL5734285 | 0.86 | ALDH1A1 (0.39) | RAB9AHPGDSMN1; SMN2POLBMAPT | |
| SCHEMBL5737136 | 0.85 | KDM4E (0.43) | RAB9AHPGDSMN1; SMN2POLBMAPT | |
| SCHEMBL5736714 | 0.85 | KDM4E (0.45) | RAB9ANPC1HPGDPOLBTP53 | |
| SCHEMBL5737133 | 0.85 | KDM4E (0.43) | RAB9AHPGDSMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1314426-B1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER LAMBERT CO (US) | 2006-02-15 | — | — | EP | claimed |
| US-6632831-B2 | Such as: (2-(2,6-Dichloro-phenylamino)-4-oxo-4H-thiazol-5-ylidene)-acet ic acid methyl ester | PFIZER INC. | 2003-10-14 | — | — | US | claimed |
| EP-1314426-A9 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-09-17 | — | — | EP | claimed |
| US-20030162779-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY | 2003-08-28 | — | — | US | claimed |
| WO-2003045384-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1314426-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1314426-B1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER LAMBERT CO (US) | 2006-02-15 | — | — | EP | disclosed |
| US-6632831-B2 | Such as: (2-(2,6-Dichloro-phenylamino)-4-oxo-4H-thiazol-5-ylidene)-acet ic acid methyl ester | PFIZER INC. | 2003-10-14 | — | — | US | disclosed |
| EP-1314426-A9 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030162779-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003045384-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1314426-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162779-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BCAT1, BCAT2, ABAT | RAB9A 2474/4885NPC1 896/4885HPGD 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.